

Henghui Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3746123/publications.pdf>

Version: 2024-02-01

82
papers

1,344
citations

394421

19
h-index

434195

31
g-index

88
all docs

88
docs citations

88
times ranked

2374
citing authors

#	ARTICLE	IF	CITATIONS
1	Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 141.	8.6	186
2	S100A4 promotes liver fibrosis via activation of hepatic stellate cells. <i>Journal of Hepatology</i> , 2015, 62, 156-164.	3.7	133
3	VEGF-D: a novel biomarker for detection of COVID-19 progression. <i>Critical Care</i> , 2020, 24, 373.	5.8	77
4	Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. <i>International Journal of Infectious Diseases</i> , 2018, 67, 92-97.	3.3	66
5	PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 193.	8.6	61
6	Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. , 2020, 8, e000374.		43
7	Mutational spectrum and precision oncology for biliary tract carcinoma. <i>Theranostics</i> , 2021, 11, 4585-4598.	10.0	39
8	Storm of soluble immune checkpoints associated with disease severity of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 192.	17.1	38
9	Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. , 2021, 9, e002356.		35
10	Persistent High Percentage of HLA-DR+CD38high CD8+ T Cells Associated With Immune Disorder and Disease Severity of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 735125.	4.8	35
11	Sendai Virus Induces Persistent Olfactory Dysfunction in a Murine Model of PVOD via Effects on Apoptosis, Cell Proliferation, and Response to Odorants. <i>PLoS ONE</i> , 2016, 11, e0159033.	2.5	34
12	Gut-derived lymphocyte recruitment to liver and induce liver injury in non-alcoholic fatty liver disease mouse model. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 676-684.	2.8	31
13	Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. <i>Scientific Reports</i> , 2018, 8, 8990.	3.3	31
14	NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 574937.	2.8	29
15	DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 549777.	2.8	26
16	The transcription factor RFX5 is a transcriptional activator of the TPP1 gene in hepatocellular carcinoma. <i>Oncology Reports</i> , 2017, 37, 289-296.	2.6	25
17	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. <i>Theranostics</i> , 2017, 7, 4753-4762.	10.0	25
18	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. <i>JAMA Network Open</i> , 2019, 2, e197621.	5.9	25

#	ARTICLE	IF	CITATIONS
19	Targeted Therapy with Anlotinib for a Patient with an Oncogenic <i>FGFR3-TACC3</i> Fusion and Recurrent Glioblastoma. <i>Oncologist</i> , 2021, 26, 173-177.	3.7	23
20	Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. , 2020, 8, e000631.		22
21	Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. , 2021, 9, e001942.		22
22	Deep sequencing of hepatitis B virus basal core promoter and precore mutants in HBeAg-positive chronic hepatitis B patients. <i>Scientific Reports</i> , 2015, 5, 17950.	3.3	21
23	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. <i>Experimental Hematology and Oncology</i> , 2020, 9, 17.	5.0	21
24	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. <i>Npj Precision Oncology</i> , 2021, 5, 36.	5.4	20
25	Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110457.	5.6	19
26	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. <i>Npj Precision Oncology</i> , 2022, 6, 2.	5.4	17
27	Dexamethasone affects mouse olfactory mucosa gene expression and attenuates genes related to neurite outgrowth. <i>International Forum of Allergy and Rhinology</i> , 2015, 5, 907-918.	2.8	16
28	The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses. <i>Aging</i> , 2021, 13, 2365-2378.	3.1	15
29	The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma. <i>Hpb</i> , 2021, 23, 1061-1071.	0.3	12
30	Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. <i>Genome Medicine</i> , 2021, 13, 175.	8.2	12
31	PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 111-120.	4.2	11
32	Abnormal CD4+T helper (Th) 1 cells and activated memory B cells are associated with type III asymptomatic mixed cryoglobulinemia in HCV infection. <i>Virology Journal</i> , 2015, 12, 100.	3.4	10
33	Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer. <i>Cancer Communications</i> , 2019, 39, 1-5.	9.2	10
34	Prognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer. <i>Cancer Communications</i> , 2020, 40, 63-66.	9.2	10
35	Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report. <i>Thoracic Cancer</i> , 2020, 11, 1094-1098.	1.9	10
36	A Machine Learning Approach Yields a Multiparameter Prognostic Marker in Liver Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 337-347.	3.4	10

#	ARTICLE	IF	CITATIONS
37	EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. <i>Aging</i> , 2021, 13, 598-618.	3.1	10
38	Characterization of the immune microenvironment in brain metastases from different solid tumors. <i>Cancer Medicine</i> , 2020, 9, 2299-2308.	2.8	9
39	Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency. , 2020, 8, e000463.		8
40	Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 1428-1445.	0.0	8
41	The mutation profiles of cell-free DNA in patients with oesophageal squamous cell carcinoma who were responsive and non-responsive to neoadjuvant chemotherapy. <i>Journal of Thoracic Disease</i> , 2020, 12, 4274-4283.	1.4	7
42	An Immunogram for an Individualized Assessment of the Antitumor Immune Response in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1189.	2.8	6
43	Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with <i>ROS1</i> -rearranged lung adenocarcinoma. , 2021, 9, e001967.		6
44	Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. <i>EBioMedicine</i> , 2021, 71, 103542.	6.1	6
45	The mutation of homologous recombination repair genetics is a potential biomarker for immunotherapy in microsatellite stable colon cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4076-4076.	1.6	6
46	The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN- α therapy outcomes in chronic hepatitis B patients. <i>BMC Infectious Diseases</i> , 2020, 20, 590.	2.9	4
47	Identification of immune checkpoint and cytokine signatures associated with the response to immune checkpoint blockade in gastrointestinal cancers. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2669-2679.	4.2	4
48	The mutational landscape of MSI-H and MSS colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15122-e15122.	1.6	4
49	Identifying tumor promoting genomic alterations in tumor-associated fibroblasts via retrovirus-insertional mutagenesis. <i>Oncotarget</i> , 2017, 8, 97231-97245.	1.8	4
50	Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. <i>Cancer Biology and Medicine</i> , 2022, 19, 1139-1149.	3.0	4
51	FOXP3 expression in FOXP3+ tumor cells promotes hepatocellular cells metastasis. <i>Translational Cancer Research</i> , 2020, 9, 5868-5881.	1.0	4
52	Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 794217.	4.8	4
53	Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 353-359.	2.0	4
54	Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1. <i>Journal of Thoracic Oncology</i> , 2020, 15, e4-e8.	1.1	3

#	ARTICLE	IF	CITATIONS
55	Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma. <i>Translational Oncology</i> , 2021, 14, 100942.	3.7	3
56	Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 767957.	2.8	3
57	Abnormal phenotypic features of IgM+B cell subsets in patients with chronic hepatitis C virus infection. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 1846-1852.	1.8	2
58	Clinical Outcome and Molecular Analysis of a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Mutation V834L. <i>Journal of Thoracic Oncology</i> , 2018, 13, e189-e191.	1.1	2
59	<p>Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5159-5167.	1.9	2
60	Ki-67 versus MammaPrint/Blueprint for assessing luminal type breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13673-e13673.	1.6	2
61	Tumor copy number alteration (CNA) burden as a prognostic factor for overall survival in Chinese gastric cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15555-e15555.	1.6	2
62	Partial recovery of disturbed VJ pairing profiles of T-cell receptor in people living with HIV receiving long-term antiretroviral therapy. <i>Science China Life Sciences</i> , 2021, 64, 152-161.	4.9	1
63	Single cell transcriptome revealed tumor associated antigen (TAA) profile in lung adenocarcinoma (LUAD). <i>Biomarker Research</i> , 2021, 9, 41.	6.8	1
64	Comparative molecular profiling of distant metastatic and non-distant metastatic lung adenocarcinoma.. <i>Neoplasia</i> , 2021, 68, 253-261.	1.6	1
65	The mutational landscape of circulating cell free DNA in patients with esophageal squamous cell carcinoma response and non-response to neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16082-e16082.	1.6	1
66	Association of HLA class I genotype with outcomes of gastrointestinal cancer patients with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16551-e16551.	1.6	1
67	Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer. <i>Current Oncology</i> , 2022, 29, 283-293.	2.2	1
68	Soluble Immune-Related Proteins as New Candidate Serum Biomarkers for the Diagnosis and Progression of Lymphangiomyomatosis. <i>Frontiers in Immunology</i> , 2022, 13, 844914.	4.8	1
69	Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9063-9063.	1.6	0
70	PD-L1 expression and TMB status in newly diagnosed metastatic non-small cell lung cancer and their effect on prognosis after EGFR-TKI or platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24294-e24294.	1.6	0
71	Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17543-e17543.	1.6	0
72	Association of high copy number instability (CNI) score with prognosis in patients with gastric cancer after surgical resection.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15552-e15552.	1.6	0

#	ARTICLE	IF	CITATIONS
73	The mutational profile analysis of different response to neoadjuvant chemoradiation therapy in local advanced esophageal squamous cell cancer patients.. Journal of Clinical Oncology, 2019, 37, e15560-e15560.	1.6	0
74	The cross talk between the molecular alterations and tumor immunity in the microenvironment in non-small-cell lung carcinoma.. Journal of Clinical Oncology, 2019, 37, e20043-e20043.	1.6	0
75	The mutational profile analysis of extramural vascular invasion in rectal cancer.. Journal of Clinical Oncology, 2019, 37, e15128-e15128.	1.6	0
76	Prediction of hepatocellular carcinoma patient survival using machine learning classification rules.. Journal of Clinical Oncology, 2019, 37, e15649-e15649.	1.6	0
77	Mutation of DNA damage repair genes confers an immune-privileged tumor microenvironment in colorectal cancer with a prognostic value.. Journal of Clinical Oncology, 2020, 38, 4080-4080.	1.6	0
78	Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer.. Journal of Clinical Oncology, 2020, 38, e16014-e16014.	1.6	0
79	Application of MammaPrint test on Chinese patient with breast cancer.. Journal of Clinical Oncology, 2020, 38, e13671-e13671.	1.6	0
80	The association of CD8 ⁺ T-cell infiltration and PD-L1 expression with prognosis of Chinese pulmonary large cell neuroendocrine carcinoma.. Journal of Clinical Oncology, 2020, 38, e21003-e21003.	1.6	0
81	PD-1 or PD-L1 co-localizes with immune cells for prediction of prognosis in non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, e21029-e21029.	1.6	0
82	Distinct transcriptional profiles in plasma exosomes associated with recurrence of nasopharyngeal carcinoma patients with standard treatment.. Journal of Clinical Oncology, 2020, 38, 6534-6534.	1.6	0